Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart sensor beat finger sticks for diabetes control?

NCT ID NCT05944432

Disease control Sponsor: Abbott Diabetes Care Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study compares continuous glucose monitoring using the FreeStyle Libre 3 sensor to standard finger-stick testing in 470 adults with type 2 diabetes whose blood sugar is not well controlled. Participants continue their usual medications (basal insulin plus SGLT2 inhibitor and/or GLP-1). The main goal is to see if the sensor improves HbA1c levels over 16 weeks. This is a management study, not a cure, as diabetes requires ongoing care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

469 people

The number who actually took part.

Started

Jul 2023

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or over. * Type 2 diabetes diagnosis for ≥1 year prior to enrolment. * Type 2 diabetes treated with a basal insulin injection regimen and SGLT2 inhibitor and/or GLP-1. * Screening HbA1c ≥59 mmol/mol to ≤97 mmol/mol (≥7.5% and ≤11.0%, inclusive). Exclusion Criteria: * Participant is currently prescribed prandial or pre-mixed (biphasic) insulin at enrolment. * Currently participating in another study that could affect glucose measurements or glucose management. * A female participant who is pregnant. * A breastfeeding female participant. * Bariatric surgical procedure within the past 12 months or is planning/scheduled for bariatric surgery within the study duration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • Cambridge University Hospital (Addenbrookes)

    Cambridge, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

  • Darlington Memorial Hospital

    Darlington, United Kingdom

  • Derriford Hospital

    Plymouth, United Kingdom

  • Hull Royal Infirmary

    Hull, United Kingdom

  • Ipswich Hospital

    Ipswich, United Kingdom

  • King's College Hospital

    London, United Kingdom

  • Leicester General Hospital

    Leicester, United Kingdom

  • Manchester Royal Infirmary

    Manchester, M13 9WU, United Kingdom

  • Moorgreen Hospital

    Southampton, United Kingdom

  • Ninewells Hospital

    Dundee, United Kingdom

  • Norfolk and Norwich University Hospital

    Norwich, United Kingdom

  • Northern General Hospital

    Sheffield, United Kingdom

  • Northwick Park Hospital

    Harrow, United Kingdom

  • Princess Alexandra Hospital

    Harlow, United Kingdom

  • Queen Alexandra Hospital

    Portsmouth, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Derby Hospital

    Derby, DE22 3NE, United Kingdom

  • Royal United Hospital

    Bath, United Kingdom

  • Singleton Hospital

    Swansea, United Kingdom

  • St James University Hospital

    Leeds, United Kingdom

  • St Mary's Hospital

    London, United Kingdom

  • Tameside General Hospital

    Ashton-under-Lyne, United Kingdom

  • The Adam Practice

    Poole, United Kingdom

  • Wishaw Hospital

    Wishaw, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.